NEUROSENSE THERAPEUTI -CW23 (NRSNW:NASDAQ)
$0.0115 0.001201 (11.6613%)
Analysed NEUROSENSE THERAPEUTI -CW23 (NRSNW:NASDAQ) News Sources
NeuroSense Advances PrimeC Toward New Drug Submission to Health Canada for ALS
22-07-2026
yahoo.com
NeuroSense Completes PrimeC Pre-NDS Process and Advances Toward December 2026 Filing with Health Canada
06-08-2026
yahoo.com
NeuroSense Issues CEO Letter to Shareholders
13-08-2026
yahoo.com
NeuroSense Unveils Accelerated, Capital-Efficient Strategy to Advance PrimeC Toward Potential Approval in ALS
31-08-2026
yahoo.com
NeuroSense to Present at H.C. Wainwright 28th Annual Global Investment Conference
10-09-2026
yahoo.com
NeuroSense Provides Business Update and Progress for the First Half of 2026
25-09-2026
yahoo.com
NeuroSense to Participate in the 5th Annual ROTH Healthcare Opportunities Conference
28-09-2026
yahoo.com
NeuroSense Provides Update on Nasdaq Listing Compliance
02-10-2026
yahoo.com
NeuroSense Secures Nasdaq Hearing Date as PrimeC Approaches Key Regulatory and Funding Milestones
13-10-2026
yahoo.com
EverythingALS to Host NeuroSense in a Community Event Named: PrimeC - Connecting the Dots
22-06-2026
yahoo.com
What is the current price of NEUROSENSE THERAPEUTI -CW23 (NRSNW:NASDAQ)?
The current price of NEUROSENSE THERAPEUTI -CW23 (NRSNW:NASDAQ) is $0.0115.
NEUROSENSE THERAPEUTI -CW23 (NRSNW:NASDAQ) absolute price change since previous trading day?
The absolute price change of NEUROSENSE THERAPEUTI -CW23 (NRSNW:NASDAQ) since the previous trading day is $0.001201.
NEUROSENSE THERAPEUTI -CW23 (NRSNW:NASDAQ) percentage price change since previous trading day?
The percentage price change of NEUROSENSE THERAPEUTI -CW23 (NRSNW:NASDAQ) since the previous trading day is 11.6613%.
What is the most recent average sentiment score for NEUROSENSE THERAPEUTI -CW23 (NRSNW:NASDAQ)?
The most recent average sentiment score for NEUROSENSE THERAPEUTI -CW23 (NRSNW:NASDAQ) is 68 out of 100.
What is the most recent average sentiment for NEUROSENSE THERAPEUTI -CW23 (NRSNW:NASDAQ)?
The most recent sentiment for NEUROSENSE THERAPEUTI -CW23 (NRSNW:NASDAQ) is .
SEC-8K** Filing Available For NEUROSENSE THERAPEUTI -CW23 (NRSNW:NASDAQ)
** material developments that could impact a company's financial condition or stock price.
Author: MattELab
MattELab is the founder and lead developer of SentientMerchant. With a Computer Science and Quantitative Finance background from a T10 university, he brings over 6 years of expertise in NLP, programmatic SEO, and full-stack development to build highly scalable AI and FinTech solutions.